LC and LC-MS/MS Studies for the Characterization of Forced Degradation Products of Tucatinib, a Novel Tyrosine Kinase Inhibitor
The growth, confirmation, and characterisation of strained shame products utilising LC-MS/MS were the main aims of the current analysis.Using an isocratic HPLC approach, tucatinib maybe calculated quantitatively at a intuitiveness of 239 nm in a plain, selective, legalized, and clear approach. An isocratic elution of samples was acted on an Inertsil ODS (250×4.6mm, 5m) line accompanying a mobile state of 70:30v/v Acetonitrile and formic acid (0.1%) brought at a flow rate of 1.0 mL/brief time period. The depravity commodity formed during the strained shame hearing were characterised utilizing MS/MS. Over the aggregation range of 5-100μg/ml, a good uninterrupted reaction was obtained. Tucatinib’s LOD and LOQ were driven expected 0.05 and 0.5, individually. The approach was quantitatively evaluated in agreements of order appropriateness, time, accuracy, veracity, and strength similarly standard directions, and the findings were raise expected inside agreeable limits. In studies on strained decay, the medication rotted in sour, soluble, and decline atmospheres. It was driven that the approach could be secondhand for standard tucatinib reasoning. Since skilled hasn’t happened some evidence of an LC-MS/MS means for quantifying tucatinib and allure degradation merchandise in the article. A system for studying the complete tucatinib depravity process has to be grown.
Author(s) Details:
S. K. Reehana,
Department of Pharmaceutical Analysis, University College of Pharmaceutical Sciences, Acharya Nagarjuna University; Nagarjuna Nagar, Guntur – 522510, Andhra Pradesh, India.
K. Sujana,
Department of Pharmaceutical Analysis, University College of Pharmaceutical Sciences, Acharya Nagarjuna University; Nagarjuna Nagar, Guntur – 522510, Andhra Pradesh, India.
A. Suneetha,
Department of Pharmaceutical Analysis, KVSR Siddhartha College of Pharmaceutical Sciences; Vijayawada – 520010, Andhra Pradesh, India.
Please see the link here: https://stm.bookpi.org/CAPR-V10/article/view/8797
Keywords: LC-MS/MS, tucatinib, method development, validation, degradation pathways